Investor Presentaiton

Zeposia (S1P agonist) Oncology Hematology Cell Therapy Immunology Cardiovascular Indication Phase/Study # of Patients YELLOWSTONE Program: Crohn's Disease (CD) - Moderate to Severe Phase III RPC01-3201 (Induction 1) N = 600 Zeposia 0.92 mg QD • Design • Placebo • Primary: Proportion of pts in clinical Phase III RPC01-3202 - (Induction 2) N = 606 Zeposia 0.92 mg QD • Placebo • - Phase III RPC01-3203 (Maintenance) N = 485 • Zeposia 0.92 mg QD • Placebo Endpoints Status CT Identifier remission (CDAI* score < 150) at week 12 . Expected data readout 2025 NCT03440372 Ill Bristol Myers Squibb Q3 2023 Results Primary: Proportion of pts in clinical remission (CDAI* score < 150) at week 12 Expected data readout 2024 • Primary: Proportion of pts in clinical remission (CDAI score of < 150) at week 52 Proportion of pts with a Simple Endoscopic Score for Crohn's Disease (SES-CD) decrease of ≥ 50% at week 52 Expected data readout 2026 (52 wks post induction & basis for filing) NCT03440385 NCT03464097 Not for Product Promotional Use 52

View entire presentation